Brief: Pfizer reaches settlement agreements with Dexcel Pharma, Hikma & Cipla for Vyndamax
April 28 (Reuters) - Pfizer Inc PFE.N: PFIZER REACHES THREE SETTLEMENT AGREEMENTS FOR VYNDAMAX PFIZER REACHES THREE SETTLEMENT AGREEMENTS FOR VYNDAMAX PFIZER: SETTLEMENTS EXTEND EFFECTIVE U.S. PATENT EXPIRY DATE FOR VYNDAMAX TO JUNE 1, 2031 PFIZER: AS A RESULT OF SETTLEMENT, REVENUES ARE NOW EXPECTED TO REMAIN RELATIVELY STABLE FROM 2028 THROUGH MID-2031 Source text: ID:nBw7SkPXwa Further company coverage: PFE.N
Recent news on Cipla
See all newsFactbox: Global healthcare companies invest billions to boost US presence
Brief: Cipla, Qilu Pharmaceutical Partner For Licensing, Supply Of Biosimilar To Keytruda In US
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Brief: Cipla Enters Exclusive Partnership With Qilu For Keytruda Biosimilar In US
Brief: Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate